About Biocon Biocon's Products & Services Research & Development Biocon's Technology Investors Media Careers CSR
  About Us
  Research & Development
  Branded Formulations
  Financial Results
  - Conference Call Invite for Q2FY17
  - Investor Presentation
  - Chairman's AGM 2016 Speech
  - Annual Reports
  Facilities Virtual Tour
  - Biocon Profile
  - CMD Profile
  - Video Gallery

 Annual Report 2016


 Biocon Malaysia

 Biocon Academy




Biocon Ltd., Asia's premier biopharmaceutical company, is committed to ensure a global right to healthcare by addressing the worldwide need for safe, effective and affordable biotherapeutics. We have harnessed the power of biotechnology through affordable innovation to enhance access to new and differentiated therapies for diseases that are chronic, where medical needs are largely unmet.

The Company is a pioneer in bringing the benefit of high quality, yet affordable, novel biologics and biosimilars to patients in India and other emerging markets. Today, we are India's largest and fully-integrated biopharmaceutical company that develops, manufactures and supplies advanced, life-saving biopharmaceuticals for diabetes, cancer and autoimmune conditions at price points that make them affordable and thus accessible.

As an innovation-led organization focused on providing affordable access, we have leveraged our inherent strengths in advanced science to develop, manufacture and deliver a rich portfolio of small molecules APIs & formulations and complex biologics – both novels and biosimilars - including monoclonal antibodies (MAbs), rh- Insulin and insulin analogs.

Our global scale capacities for manufacturing high quality, affordable biologics have positioned us as the world’s fourth largest insulins producer, enabling us to address the growing needs of diabetes patients across the globe. As one of the leading oncology companies in India, we have brought safe, efficacious and affordable medicines for cancer to cater to the needs of patients, caregivers and medical practitioners in the country.





Q2FY17 Highlights
Stock Update

  Latest Press Release

 Oct. 20, 2016:
 Biocon Q2 FY17 Revenue Up  21%; EBITDA Up 45%;  Revenues at Rs 992 Crs.;  EBITDA at Rs 277 Crs.; Net  Profit at Rs 147 Crs.

 Sept. 19, 2016:
 Biocon appoints Suresh  Subramanian as Head of  Branded Formulations  (India) Business 

 Sept. 01, 2016:

 Kiran Mazumdar Shaw  Appointed 'Knight of the  Legion of Honour' by the  Government of France 

 Aug. 25, 2016:

 Mylan and Biocon Announce  Regulatory Submission for  Proposed Biosimilar  Trastuzumab Accepted for  Review by European  Medicines Agency

  Media Coverage

October, 2016:
Biocon gears up to launch new drugs to treat diabetes, cancer

September, 2016:

Top French Honour for Biocon's Kiran Shaw

August, 2016:
'We have enhanced patient access to insulin across India' - Kiran Mazumdar Shaw







Recommended sites Biocon on  
About Us

Investor Relations
Media Relations
Site Map
Contact Us
Our Growth Accelerators
Fact Sheet
Branded Formulations
Research Services
Active Discovery Program

Karnataka Vision Group on BT
Syngene International
Biocon Academy

    Linked In   
  Report adverse event/side effects and product complaints    
  * Disclaimer            © 2016, Biocon. All Rights Reserved